Full Text:   <2580>

Summary:  <1957>

CLC number: R587.1

On-line Access: 2014-06-07

Received: 2014-01-25

Revision Accepted: 2014-04-17

Crosschecked: 2014-05-12

Cited: 8

Clicked: 5493

Citations:  Bibtex RefMan EndNote GB/T7714

-   Go to

Article info.
Open peer comments

Journal of Zhejiang University SCIENCE B 2014 Vol.15 No.6 P.575-581


A preliminary evaluation of VEGF-A, VEGFR1 and VEGFR2 in patients with well-controlled type 2 diabetes mellitus*

Author(s):  Barbara Ruszkowska-Ciastek1, Alina Sokup1, Maciej W. Socha2, Zofia Ruprecht3, Lidia Hałas1, Barbara Gralczyk1, Krzysztof Gralczyk1, Grażyna Gadomska1, Danuta Rość1

Affiliation(s):  1. Department of Pathophysiology, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, Poland; more

Corresponding email(s):   ruszkowska.basia@gmail.com

Key Words:  Type 2 Diabetes, Angiogenesis, Lipid abnormalities, Glycated hemoglobin (HbA1c)

Barbara Ruszkowska-Ciastek, Alina Sokup, Maciej W. Socha, Zofia Ruprecht, Lidia Ha?as, Barbara Gralczyk, Krzysztof Gralczyk, Gra?yna Gadomska, Danuta Ro??. A preliminary evaluation of VEGF-A, VEGFR1 and VEGFR2 in patients with well-controlled type 2 diabetes mellitus[J]. Journal of Zhejiang University Science B, 2014, 15(6): 575-581.

@article{title="A preliminary evaluation of VEGF-A, VEGFR1 and VEGFR2 in patients with well-controlled type 2 diabetes mellitus",
author="Barbara Ruszkowska-Ciastek, Alina Sokup, Maciej W. Socha, Zofia Ruprecht, Lidia Ha?as, Barbara Gralczyk, Krzysztof Gralczyk, Gra?yna Gadomska, Danuta Ro??",
journal="Journal of Zhejiang University Science B",
publisher="Zhejiang University Press & Springer",

%0 Journal Article
%T A preliminary evaluation of VEGF-A, VEGFR1 and VEGFR2 in patients with well-controlled type 2 diabetes mellitus
%A Barbara Ruszkowska-Ciastek
%A Alina Sokup
%A Maciej W. Socha
%A Zofia Ruprecht
%A Lidia Ha?as
%A Barbara Gralczyk
%A Krzysztof Gralczyk
%A Gra?yna Gadomska
%A Danuta Ro??
%J Journal of Zhejiang University SCIENCE B
%V 15
%N 6
%P 575-581
%@ 1673-1581
%D 2014
%I Zhejiang University Press & Springer
%DOI 10.1631/jzus.B1400024

T1 - A preliminary evaluation of VEGF-A, VEGFR1 and VEGFR2 in patients with well-controlled type 2 diabetes mellitus
A1 - Barbara Ruszkowska-Ciastek
A1 - Alina Sokup
A1 - Maciej W. Socha
A1 - Zofia Ruprecht
A1 - Lidia Ha?as
A1 - Barbara Gralczyk
A1 - Krzysztof Gralczyk
A1 - Gra?yna Gadomska
A1 - Danuta Ro??
J0 - Journal of Zhejiang University Science B
VL - 15
IS - 6
SP - 575
EP - 581
%@ 1673-1581
Y1 - 2014
PB - Zhejiang University Press & Springer
ER -
DOI - 10.1631/jzus.B1400024

Objective: Decompensated chronic hyperglycemia often leads to late microvascular complications such as retinopathy, diabetic foot syndrome, and diabetic kidney disease. The aim of this study was to determine the concentration of vascular endothelial growth factor A (VEGF-A) and its receptors in patients with well-controlled diabetes. Methods: The study was conducted on 31 patients with well-controlled type 2 Diabetes without micro- or macroangiopathy. Thirty healthy volunteers were enrolled in a control group. Serum concentrations of VEGF-A, VEGF receptors 1 and 2 (VEGFR1 and VEGFR2), fasting glucose, and lipid profiles were measured, and the plasma concentration of glycated hemoglobin (HbA1c) was determined. Results: No significant differences were observed between the concentration of VEGF-A, VEGFR1 or VEGFR2 in the subject group and that in the control group. Positive correlations were noted between the levels of VEGF-A, VEGFR2, and triglyceride, and there was a negative correlation between the levels of VEGFR2 and high-density lipoprotein (HDL)-cholesterol in the study group. Conclusions: The concentrations of VEGF-A and its receptors 1 and 2 in patients with well-controlled diabetes are comparable to those of healthy individuals, which may indicate that appropriate control of glucose levels delays the occurrence of vascular complications. A negative correlation between VEGFR2 and HDL-cholesterol levels, and positive correlations between VEGF-A, VEGFR2, and triglyceride levels, suggest that lipid abnormalities occurring in diabetes may be involved in the modulation of angiogenesis.




Darkslateblue:Affiliate; Royal Blue:Author; Turquoise:Article


[1] Araszkiewicz, A., Zozulińska, D., Wierusz-Wysocka, B., 2004. Assessment of vascular-endothelial growth factor (VEGF) serum concentration in type 1 diabetic subject. Diabet Dosw Klin, (in Polish),4(S3):197-201. 

[2] Barańska, P., Jerczyńska, H., Pawłowska, Z., 2005. Vascular endothelial growth factor—structure and functions. Postepy Biochem, (in Polish),51(1):12-21. 

[3] Basha, B., Samuel, S.M., Triggle, C.R., 2012. Endothelial dysfunction in diabetes mellitus: possible involvement of endoplasmic reticulum stress?. Exp Diabetes Res, 2012:481840

[4] Cameron, N.E., Eaton, S.E.M., Cotter, M.A., 2001. Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy. Diabetologia, 44(11):1973-1988. 

[5] Cooper, M., Vranes, D., Youssef, S., 1999. Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes. Diabetes, 48(11):2229-2238. 

[6] Derzhko, R., Witkowska, M., 2006. Glucose metabolism disturbances and the risk of cardiovascular diseases. Adv Clin Exp Med, 15(5):911-916. 

[7] Gumbrecht, J., 2004. Insulin and endothelium. Przew Lek, (in Polish),7:58-61. 

[8] International Diabetes Federation, 2012.  Diabetes Atlas. Brussels,Belgium :

[9] Janota, J., Pomyje, J., Toth, D., 2003. Expression of angiopoietic factors in normal and type-I diabetes human placenta: a pilot study. Eur J Obstet Gynecol Reprod Biol, 111(2):153-156. 

[10] Jansson, P.A., 2007. Endothelial dysfunction in insulin resistance and type 2 diabetes. J Intern Med, 262(2):173-183. 

[11] Kieć-Wilk, B., Dudek, W., Dembińska-Kieć, A., 2006. Nutrigenomics, angiogenesis and obesity. Acta Angiol, 12(4):141-148. 

[12] Kim, H.N., Oh, H.J., Seo, A.J., 2005. Vascular endothelial growth factor (VEGF) and soluble VEGF receptor FLT-1 in diabetic nephropathy. Kidney Int, 67(1):167-177. 

[13] Kowalski, J., Śliwczyńska-Rodziewicz, D., Kowalczyk, E., 2011. Plasma nitric oxide and vascular endothelial growth factor levels in patients with metabolic syndrome and co-existing vascular complications. Pol Merkur Lekarski, (in Polish),30(178):249-252. 

[14] Kubisz, P., Chudy, P., Staśko, J., 2010. Circulating vascular endothelial growth factor in the normo- and/or microalbuminuric patients with type 2 diabetes mellitus. Acta Diabetol, 47(2):119-124. 

[15] Mahdy, R.A., Nada, W.M., Hadhoud, K.M., 2010. The role of vascular endothelial growth factor in the progression of diabetic vascular complications. Eye, 24(10):1576-1584. 

[16] Olokoba, A.B., Obateru, O.A., Olokoba, L.B., 2012. Type 2 diabetes mellitus: a review of current trends. Oman Med J, 27(4):269-273. 

[17] Pacholczyk, M., Ferenc, T., Kowalski, J., 2008. The metabolic syndrome. Part II: its mechanisms of development and its complications. Postepy Hig Med Dosw, (in Polish),62:543-558. 

[18] Peczyńska, J., Urban, M., Urban, B., 2004. Assessment of growth factor levels in adolescents with type 1 diabetes mellitus and the beginning of diabetic microangiopathy. Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw, (in Polish),10(1):41-48. 

[19] Santilli, F., Spagnoli, A., Mohn, A., 2001. Increased vascular endothelial growth factor serum concentrations may help to identify patients with onset of type 1 diabetes during childhood at risk for developing persistent microalbuminuria. J Clin Endocrinol Metab, 86(8):3871

[20] Skra, J., Biegus, J., Pupka, A., 2006. Molecular basics of angiogenesis. Postepy Hig Med Dosw, (in Polish),60:410-415. 

[21] Stuttfeld, E., Ballmer-Hofer, K., 2009. Structure and function of VEGF receptors. IUBMB Life, 61(9):915-922. 

[22] Swidzińska, E., Naumnik, W., Chyczewska, E., 2006. Angiogenesis and neoangiogenesis—the role in lung cancer and other tumors. Pneumonol Alergol Pol, (in Polish),74(4):414-420. 

[23] Wada, H., Ura, S., Kitajka, S., 2011. Distinct characteristics of circulating vascular endothelial growth factor-A and C levels in human subjects. PLoS ONE, 6(12):e29351

[24] Witmer, A.N., Blaauwgeers, H.G., Weich, H.A., 2002. Altered expression patterns of VEGF receptors in human diabetic retina and in experimental VEGF-induced retinopathy in monkey. Invest Ophthalmol Vis Sci, 43(3):849-857. 

[25] World Health Organization, 2011. Global Status Report on Noncommunicable Diseases 2010. , (Available from )http://www.who.int/nmh/publications/ncd_report_full_en.pdf,:

[26] Zielonka, T.M., 2004. Angiogenesis. Part II. Factors that modulate the process of formation of new blood vessels. Alergy Asthma Immunol, 9(1):25-31. 

Open peer comments: Debate/Discuss/Question/Opinion


Please provide your name, email address and a comment

Journal of Zhejiang University-SCIENCE, 38 Zheda Road, Hangzhou 310027, China
Tel: +86-571-87952783; E-mail: cjzhang@zju.edu.cn
Copyright © 2000 - 2023 Journal of Zhejiang University-SCIENCE